9/9
08:07 am
aktx
Akari Therapeutics (NASDAQ:AKTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $1.60 price target on the stock.
Low
Report
Akari Therapeutics (NASDAQ:AKTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $1.60 price target on the stock.